US FDA to increase misdemeanour prosecutions of pharma executives
This article was originally published in SRA
Executive Summary
Pharmaceutical and medtech executives responsible for assuring compliance with relevant US Food and Drug Administration regulations for products manufactured by their companies may face increased “misdemeanor prosecutions” if they fall short in their designated role.